MedTrace Logo

A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration

NCT00395057 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2015-09-07

Study results available
· View outcomes & findings →

Summary

This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration

Conditions

  • Choroid Neovascularization
  • Age-Related Macular Degeneration

Interventions

DRUG

AGN 211745

AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2

DRUG

AGN 211745

AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2

DRUG

AGN 211745

AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2

DRUG

Ranibizumab 500µg

Ranibizumab 500µg injections at Day 1, Month 1, Month 2

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-10-31
Completion
2009-02-28

Countries

  • United States
  • Australia
  • Philippines

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00395057 on ClinicalTrials.gov